Grifols, S.A. (NASDAQ:GRFS) Short Interest Down 28.9% in March

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 2,710,000 shares, a decrease of 28.9% from the February 28th total of 3,810,000 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 991,800 shares, the short-interest ratio is currently 2.7 days.

Grifols Price Performance

Shares of GRFS stock traded down $0.16 during trading hours on Monday, reaching $7.11. The company had a trading volume of 1,156,487 shares, compared to its average volume of 1,231,193. Grifols has a 12-month low of $5.79 and a 12-month high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The company has a market capitalization of $4.89 billion, a price-to-earnings ratio of 6.08 and a beta of 0.35. The stock has a fifty day moving average of $7.56 and a 200-day moving average of $8.04.

Hedge Funds Weigh In On Grifols

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 1,546 shares during the period. Charles Schwab Investment Management Inc. increased its position in Grifols by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 1,657 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Grifols by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 2,403 shares during the period. Finally, R Squared Ltd acquired a new position in Grifols in the 4th quarter valued at about $28,000.

Wall Street Analyst Weigh In

Separately, Morgan Stanley began coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.